The Role of Taxanes in the Management of Bladder Cancer

The Role of Taxanes in the Management of Bladder Cancer Matthew D. Galsky Oncologist 2005; 10: 792-798 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in genitourinary cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: List the prognostic factors that are the best predictors of outcome for patients with metastatic bladder cancer. Interpret the results of the completed phase III trials comparing MVAC with taxane-based regimens in patients with metastatic bladder cancer. Describe the ongoing multinational phase III trial using taxane-based therapy in patients with metastatic bladder cancer. Define the role of taxanes as perioperative therapy in patients with localized bladder cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 28, 2005 Most Recent Review: Nov. 28, 2005* Most Recent Update: Nov. 28, 2005 Date Credit Expires: Nov. 28, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.